SCHEMBL4501302

SCHEMBL4501302

O=C1COc2ccncc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.41
MAOA P21397 2/20 0.39
CDC25B P30305 1/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
ATM Q13315 1/20 0.36
CYP19A1 P11511 1/20 0.36
AAK1 Q2M2I8 4/20 0.35
PSMB5 P28074 1/20 0.35
HSD17B10 Q99714 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4822863 0.84 MAOB (0.39) MAOBMAOACDC25BCYP11B1CYP11B2
Hydrochloric Acid SCHEMBL3597821 0.82 MAOB (0.38) MAOBMAOACDC25BCYP11B1CYP11B2
SCHEMBL13708804 0.81 MAOB (0.46) MAOBMAOACDC25BCYP11B1CYP11B2
SCHEMBL11557933 0.73 KMT2A (0.49) MAOBMAOAMAPTAAK1MEN1
SCHEMBL11660603 0.72 MAOB (0.55) MAOBMAOASMN1; SMN2MAPTATM
SCHEMBL31618253 0.71 MAOA (0.38) MAOBMAOACDC25BCYP11B1CYP11B2
SCHEMBL13708805 0.70 MAOB (0.71) MAOBSMN1; SMN2MAPTATMMEN1
3-Coumaranone SCHEMBL29420742 0.70 PKM (0.56) MAOBMAOASMN1; SMN2MAPTATM
3-Coumaranone SCHEMBL69412 0.70 PKM (0.56) MAOBMAOASMN1; SMN2MAPTATM
SCHEMBL9923730 0.69 KMT2A (0.32) MAOBKMT2AROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006119820-A1 AGENTS FOR DYEING KERATIN-BASED FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-11-16 WO claimed
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR MEDSHINE DISCOVERY INC. (CN) 2023-11-02 US disclosed
US-8957219-B2 Acetic acid amide derivative having inhibitory activity on endothelial lipase SHIONOGI & CO., LTD. (JP) 2015-02-17 US disclosed
US-20140288302-A1 ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE SHIONOGI & CO., LTD. (JP) 2014-09-25 US disclosed
US-20110251386-A1 ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE SHIONOGI & CO., LTD. (JP) 2011-10-13 US disclosed
US-7544693-B2 Spirofuropyridine aryl derivatives ASTRAZENECA AB (SE) 2009-06-09 US disclosed
US-20070072887-A1 Spirofuropyridine aryl derivatives ASTRAZENECA AB (SE) 2007-03-29 US disclosed
EP-1678183-A1 SPIROFUROPYRIDINE ARYL DERIVATIVES AstraZeneca AB (SE) 2006-07-12 EP disclosed
WO-2005042538-A1 SPIROFUROPYRIDINE ARYL DERIVATIVES ASTRAZENECA AB (SE) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR CRBN, CRKL, NCOR1 MAOB 4108/4885MAOA 4359/4885CDC25B 3313/4885
US-20070072887-A1 Spirofuropyridine aryl derivatives REN, ADRA1D, ADRB1 MAOB 181/4885MAOA 420/4885CDC25B 3059/4885
US-20110251386-A1 ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE LIPG, CEL, LIPA MAOB 568/4885MAOA 458/4885CDC25B 4223/4885
US-20140288302-A1 ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE LIPG, CEL, FFAR3 MAOB 536/4885MAOA 473/4885CDC25B 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.